Prostate-specific antigen best practice policy—part II: prostate cancer staging and post-treatment follow-up
- 1 February 2001
- Vol. 57 (2) , 225-229
- https://doi.org/10.1016/s0090-4295(00)00994-8
Abstract
No abstract availableThis publication has 34 references indexed in Scilit:
- LIMITED ROLE OF RADIONUCLIDE BONE SCINTIGRAPHY IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN ELEVATIONS AFTER RADICAL PROSTATECTOMYJournal of Urology, 1998
- The PSA nadir that indicates potential cure after radiotherapy for prostate cancerUrology, 1997
- Serum Markers as a Predictor of Response Duration and Patient Survival After Hormonal Therapy for Metastatic Carcinoma of the ProstateJournal of Urology, 1997
- The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostateBJU International, 1996
- Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate Cancer: The relationship between nadir level and disease-free survivalJournal of Urology, 1996
- Endo-Rectal Coil Magnetic Resonance Imaging in Clinically Localized Prostate Cancer: Is it Accurate?Journal of Urology, 1996
- Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer?British Journal of Urology, 1995
- Original Articles: Prostate Cancer: The Use and Accuracy of Cross-Sectional Imaging and Fine Needle Aspiration Cytology for Detection of Pelvic Lymph Node Metastases Before Radical ProstatectomyJournal of Urology, 1995
- Salvage Radical Prostatectomy: Outcome Measured by Serum Prostate Specific Antigen LevelsJournal of Urology, 1995
- Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancerUrology, 1994